ESCMID*  	ESCMID*  	 NNP	B-NP
guideline  	guideline  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
diagnosis  	diagnosis  	 NN	O
and  	and  	 CC	O
management  	management  	 NN	O
of  	of  	 IN	O
Candida  	Candida  	 NNP	B-NP
diseases  	diseases  	 VBD	I-NP
2012 	2012 	 CD	O
:  	:  	 :	O
adults  	adults  	 NNS	O
with  	with  	 IN	O
haematological  	haematological  	 JJ	B-NP
malignancies  	malignancies  	 NN	I-NP
and  	and  	 CC	O
after  	after  	 IN	O
haematopoietic  	haematopoietic  	 JJ	B-NP
stem  	stem  	 NN	I-NP
cell  	cell  	 NN	I-NP
transplantation  	transplantation  	 NN	I-NP
( 	( 	 -LRB-	O
HCT 	HCT 	 NNP	B-NP
)  	)  	 -RRB-	O
Fungal  	Fungal  	 NNP	B-NP
diseases  	diseases  	 NNS	I-NP
still  	still  	 RB	O
play  	play  	 VB	O
a  	a  	 DT	O
major  	major  	 JJ	O
role  	role  	 NN	O
in  	in  	 IN	O
morbidity  	morbidity  	 NN	O
and  	and  	 CC	O
mortality  	mortality  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
haematological  	haematological  	 JJ	B-NP
malignancies 	malignancies 	 NN	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
those  	those  	 DT	O
undergoing  	undergoing  	 JJ	O
haematopoietic  	haematopoietic  	 NNS	B-NP
stem  	stem  	 VBP	O
cell  	cell  	 NN	B-NP
transplantation 	transplantation 	 NN	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
Aspergillus  	Aspergillus  	 NNP	B-NP
and  	and  	 CC	O
other  	other  	 JJ	O
filamentous  	filamentous  	 JJ	B-NP
fungal  	fungal  	 JJ	I-NP
diseases  	diseases  	 NNS	I-NP
remain  	remain  	 VBP	O
a  	a  	 DT	O
major  	major  	 JJ	O
concern 	concern 	 NN	O
,  	,  	 ,	O
Candida  	Candida  	 NNP	B-NP
infections  	infections  	 NNS	I-NP
are  	are  	 VBP	O
still  	still  	 RB	O
a  	a  	 DT	O
major  	major  	 JJ	O
cause  	cause  	 NN	O
of  	of  	 IN	O
mortality 	mortality 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
ESCMID  	ESCMID  	 NNP	B-NP
guidelines  	guidelines  	 NNS	I-NP
focuses  	focuses  	 VBZ	O
on  	on  	 IN	O
this  	this  	 DT	O
patient  	patient  	 JJ	O
population  	population  	 NN	O
and  	and  	 CC	O
reviews  	reviews  	 NNS	O
pertaining  	pertaining  	 VBP	O
to  	to  	 TO	O
prophylaxis 	prophylaxis 	 VB	B-NP
,  	,  	 ,	O
empirical 	empirical 	 CD	B-NP
/ 	/ 	 CD	I-NP
pre-emptive  	pre-emptive  	 JJ	I-NP
and  	and  	 CC	O
targeted  	targeted  	 JJ	O
therapy  	therapy  	 NN	O
of  	of  	 IN	O
Candida  	Candida  	 NNP	B-NP
diseases 	diseases 	 NNS	I-NP
.  	.  	 .	O
Anti-Candida  	Anti-Candida  	 JJ	B-NP
prophylaxis  	prophylaxis  	 NN	I-NP
is  	is  	 VBZ	O
only  	only  	 RB	O
recommended  	recommended  	 VBN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
receiving  	receiving  	 VBG	O
allogeneic  	allogeneic  	 JJ	B-NP
stem  	stem  	 NN	I-NP
cell  	cell  	 NN	I-NP
transplantation 	transplantation 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
authors  	authors  	 NNS	O
recognize  	recognize  	 VBP	O
that  	that  	 IN	O
the  	the  	 DT	O
recommendations  	recommendations  	 NNS	B-NP
would  	would  	 MD	O
have  	have  	 VB	O
most  	most  	 RBS	O
likely  	likely  	 RB	O
been  	been  	 VBN	O
different  	different  	 JJ	O
if  	if  	 IN	O
the  	the  	 DT	O
purpose  	purpose  	 NN	O
would  	would  	 MD	O
have  	have  	 VB	O
been  	been  	 VBN	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
all  	all  	 DT	O
fungal  	fungal  	 JJ	B-NP
infections  	infections  	 NNS	I-NP
( 	( 	 -LRB-	O
e.g.  	e.g.  	 FW	O
aspergillosis 	aspergillosis 	 FW	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
targeted  	targeted  	 JJ	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
candidaemia 	candidaemia 	 NN	B-NP
,  	,  	 ,	O
recommendations  	recommendations  	 NNS	B-NP
for  	for  	 IN	O
treatment  	treatment  	 NN	O
are  	are  	 VBP	O
available  	available  	 JJ	O
for  	for  	 IN	O
all  	all  	 DT	O
echinocandins 	echinocandins 	 NN	B-NP
,  	,  	 ,	O
that  	that  	 WDT	O
is  	is  	 VBZ	O
anidulafungin  	anidulafungin  	 JJ	B-NP
( 	( 	 -LRB-	O
AI 	AI 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
caspofungin  	caspofungin  	 NNS	B-NP
( 	( 	 -LRB-	O
AI 	AI 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
micafungin  	micafungin  	 NNS	B-NP
( 	( 	 -LRB-	O
AI 	AI 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
although  	although  	 IN	O
a  	a  	 DT	O
warning  	warning  	 NN	O
for  	for  	 IN	O
resistance  	resistance  	 NN	O
is  	is  	 VBZ	O
expressed 	expressed 	 VBN	O
.  	.  	 .	O
Liposomal  	Liposomal  	 NNP	B-NP
amphotericin  	amphotericin  	 VBD	O
B  	B  	 NNP	O
received  	received  	 VBD	O
a  	a  	 DT	O
BI  	BI  	 NNP	B-NP
recommendation  	recommendation  	 NN	I-NP
due  	due  	 JJ	O
to  	to  	 TO	O
higher  	higher  	 JJR	O
number  	number  	 NN	O
of  	of  	 IN	O
reported  	reported  	 VBN	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
trials 	trials 	 NNS	O
.  	.  	 .	O
Amphotericin  	Amphotericin  	 NNP	B-NP
B  	B  	 NNP	I-NP
deoxycholate  	deoxycholate  	 NN	I-NP
should  	should  	 MD	O
not  	not  	 RB	O
be  	be  	 VB	O
used  	used  	 VBN	O
( 	( 	 -LRB-	O
DII 	DII 	 NNP	B-NP
) 	) 	 -RRB-	O
;  	;  	 :	O
and  	and  	 CC	O
fluconazole  	fluconazole  	 NNS	B-NP
was  	was  	 VBD	O
rated  	rated  	 VBN	O
CI  	CI  	 NNP	O
because  	because  	 IN	O
of  	of  	 IN	O
a  	a  	 DT	O
change  	change  	 NN	O
in  	in  	 IN	O
epidemiology  	epidemiology  	 NN	O
in  	in  	 IN	O
some  	some  	 DT	O
areas  	areas  	 NNS	O
in  	in  	 IN	O
Europe 	Europe 	 NNP	O
.  	.  	 .	O
Removal  	Removal  	 NN	O
of  	of  	 IN	O
central  	central  	 JJ	O
venous  	venous  	 JJ	B-NP
catheters  	catheters  	 NN	I-NP
is  	is  	 VBZ	O
recommended  	recommended  	 VBN	O
during  	during  	 IN	O
candidaemia  	candidaemia  	 NN	B-NP
but  	but  	 CC	O
if  	if  	 IN	O
catheter  	catheter  	 JJ	B-NP
retention  	retention  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
clinical  	clinical  	 JJ	B-NP
necessity 	necessity 	 NN	I-NP
,  	,  	 ,	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
an  	an  	 DT	O
echinocandin  	echinocandin  	 NN	B-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
option  	option  	 NN	O
( 	( 	 -LRB-	O
CII 	CII 	 NNP	B-NP
( 	( 	 -LRB-	I-NP
t 	t 	 LS	I-NP
)  	)  	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
chronic  	chronic  	 JJ	B-NP
disseminated  	disseminated  	 JJ	I-NP
candidiasis  	candidiasis  	 JJ	I-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
recommendations  	recommendations  	 NNS	B-NP
are  	are  	 VBP	O
liposomal  	liposomal  	 JJ	B-NP
amphotericin  	amphotericin  	 JJ	I-NP
B  	B  	 NN	I-NP
for  	for  	 IN	O
8  	8  	 CD	O
weeks  	weeks  	 NNS	O
( 	( 	 -LRB-	O
AIII 	AIII 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
fluconazole  	fluconazole  	 VBG	O
for  	for  	 IN	O
> 	> 	 CD	O
3  	3  	 CD	O
months  	months  	 NNS	O
or  	or  	 CC	O
other  	other  	 JJ	O
azoles  	azoles  	 NNS	B-NP
( 	( 	 -LRB-	O
BIII 	BIII 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Granulocyte  	Granulocyte  	 JJ	B-NP
transfusions  	transfusions  	 NNS	I-NP
are  	are  	 VBP	O
only  	only  	 RB	O
an  	an  	 DT	O
option  	option  	 NN	O
in  	in  	 IN	O
desperate  	desperate  	 JJ	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
Candida  	Candida  	 NNP	B-NP
disease  	disease  	 NN	I-NP
and  	and  	 CC	O
neutropenia  	neutropenia  	 NNS	B-NP
( 	( 	 -LRB-	O
CIII 	CIII 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
